Last reviewed · How we verify
Comparator: M-M-R II — Competitive Intelligence Brief
phase 3
Live attenuated vaccine
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Comparator: M-M-R II (Comparator: M-M-R II) — Merck Sharp & Dohme LLC. M-M-R II is a live attenuated viral vaccine that stimulates immune response against measles, mumps, and rubella by introducing weakened forms of these viruses.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Comparator: M-M-R II TARGET | Comparator: M-M-R II | Merck Sharp & Dohme LLC | phase 3 | Live attenuated vaccine | ||
| MMR vaccination | MMR vaccination | Klara M. Pósfay Barbe | marketed | Live attenuated vaccine | ||
| varicella-5 | varicella-5 | Changchun Keygen Biological Products Co., Ltd. | marketed | Live attenuated vaccine | Varicella-zoster virus | |
| Varicella Virus Vaccine Live | Varicella Virus Vaccine Live | Sanofi Pasteur, a Sanofi Company | marketed | Live attenuated vaccine | Varicella-zoster virus (VZV) | |
| Pentavalent rotavirus vaccine | Pentavalent rotavirus vaccine | Sanofi Pasteur, a Sanofi Company | marketed | Live attenuated vaccine | ||
| Stamaril, Sanofi Pasteur | Stamaril, Sanofi Pasteur | Epicentre | marketed | Live attenuated vaccine | Yellow fever virus (17D strain) | |
| MMRvaxpro | MMRvaxpro | Rigshospitalet, Denmark | marketed | Live attenuated vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Live attenuated vaccine class)
- GlaxoSmithKline · 19 drugs in this class
- Merck Sharp & Dohme LLC · 11 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
- PATH · 5 drugs in this class
- Sanofi · 5 drugs in this class
- Bandim Health Project · 5 drugs in this class
- Centers for Disease Control and Prevention · 3 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
- Beijing Center for Disease Control and Prevention · 2 drugs in this class
- Aga Khan University · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Comparator: M-M-R II CI watch — RSS
- Comparator: M-M-R II CI watch — Atom
- Comparator: M-M-R II CI watch — JSON
- Comparator: M-M-R II alone — RSS
- Whole Live attenuated vaccine class — RSS
Cite this brief
Drug Landscape (2026). Comparator: M-M-R II — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-m-m-r-ii. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing